Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Design Therapeutics, Inc.DSGN · Entity 4991 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Design Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-08 | Direct | 30,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Entasis Therapeutics Holdings Inc.
Report date July 07, 2022 · Filed July 11, 2022
Section 16 reporting ended · disclosed 2022-07-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-07 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2022-07-07 · Other · Disposed 22,000 · Balance 0 F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2022-07-11 · Disposition to issuer · Disposed 27,500 · Balance 0 F2: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-11 · Other · Disposed 17,307 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.98 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-11 · Other · Disposed 11,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price").
F2: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20.
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:15 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001751873-26-000002 · form4-06112026_040606.xml · derivative · entry 1 Berger Heather A. · CIK 0001751873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:30 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001415889-25-016956 · form4-06122025_040606.xml · derivative · entry 1 Berger Heather A. · CIK 0001751873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2035-06-09 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 10, 2025 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:00 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001415889-24-017238 · form4-06172024_050614.xml · derivative · entry 1 Berger Heather A. · CIK 0001751873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 13, 2024 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| March 25, 2024 Filed Mar 25, 2024 23:09 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 1,300 | $3.74 | $4,865.77 |
DisclosureSEC source: 0001415889-24-009062 · form4-03252024_110307.xml · nonDerivative · entry 1 Berger Heather A. · CIK 0001751873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300 Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.63 | $0.00 |
DisclosureSEC source: 0001209191-23-033781 · doc4.xml · derivative · entry 1 Berger Heather A. · CIK 0001751873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 16:04 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001104659-22-078788 · tm2220760-2_4seq1.xml · derivative · entry 4 Berger Heather A. · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 16:04 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 17,307 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001104659-22-078788 · tm2220760-2_4seq1.xml · derivative · entry 3 Berger Heather A. · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,307 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 16:04 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerCommon Stock | 27,500 | $2.20 | $60,500.00 |
DisclosureSEC source: 0001104659-22-078788 · tm2220760-2_4seq1.xml · nonDerivative · entry 2 Berger Heather A. · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. F2 · price: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 16:04 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherCommon Stock | 22,000 | $2.20 | $48,400.00 |
DisclosureSEC source: 0001104659-22-078788 · tm2220760-2_4seq1.xml · nonDerivative · entry 1 Berger Heather A. · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). F1 · price: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:05 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001209191-22-037503 · doc4.xml · derivative · entry 1 Berger Heather A. · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 15, 2022 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| January 18, 2022 Filed Jan 19, 2022 16:02 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005418 · tm223320-6_4seq1.xml · nonDerivative · entry 1 Behanna Heather · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,500 F1 · shares: This award vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service as a director of the Company. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 16:02 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 5,769 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001104659-22-023772 · tm226724-4_4seq1.xml · derivative · entry 4 Behanna Heather · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,769 Underlying: Common Stock · 5,769 shares Expires 2031-07-15 F5 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 7,500 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 5,769 shares of issuer's common stock, having an exercise price of $2.44 per share. F6 · derivative.exercise_date: The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 16:02 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $6.12 | Not disclosed |
DisclosureSEC source: 0001104659-22-023772 · tm226724-4_4seq1.xml · derivative · entry 3 Behanna Heather · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2029-06-18 F5 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 7,500 shares of issuer's common stock granted to the Reporting Person on June 19, 2019. In exchange, the Reporting Person received a replacement option for 5,769 shares of issuer's common stock, having an exercise price of $2.44 per share. F4 · derivative.exercise_date: The option provided for vesting as follows: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 16:02 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 11,538 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001104659-22-023772 · tm226724-4_4seq1.xml · derivative · entry 2 Behanna Heather · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2031-07-15 F2 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 11,538 shares of issuer's common stock, having an exercise price of $2.44 per share. F3 · derivative.exercise_date: The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 16:02 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $5.66 | Not disclosed |
DisclosureSEC source: 0001104659-22-023772 · tm226724-4_4seq1.xml · derivative · entry 1 Behanna Heather · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-01-17 F2 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 11,538 shares of issuer's common stock, having an exercise price of $2.44 per share. F1 · derivative.exercise_date: The option provided for vesting as follows: The shares subject to this option will vest in full on January 1, 2020, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 21:17 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $27.04 | $0.00 |
DisclosureSEC source: 0001209191-21-040988 · doc4.xml · derivative · entry 1 Behanna Heather · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over a three year period following June 15, 2021 (the "Grant Date") such that the option is fully vested on the third anniversary of the Grant Date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 10:35 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-045914 · tm2111994-3_4seq1.xml · nonDerivative · entry 1 Behanna Heather · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Read SEC document |
| June 10, 2020 Filed Oct 6, 2020 16:32 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001104659-20-112659 · a4.xml · derivative · entry 1 Behanna Heather · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:03 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0001104659-19-037004 · a4.xml · derivative · entry 1 Behanna Heather · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-18 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 16:56 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.66 | $0.00 |
DisclosureSEC source: 0001209191-19-004765 · doc4.xml · derivative · entry 1 Behanna Heather · CIK 0001751873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-01-17 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on January 1, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.